|

Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

RECRUITINGN/ASponsored by Meyer Children's Hospital IRCCS
Actively Recruiting
PhaseN/A
SponsorMeyer Children's Hospital IRCCS
Started2024-11-04
Est. completion2026-03-30
Eligibility
Age2 Years – 13 Years
Healthy vol.Accepted

Summary

Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis. This is a pilot study on screening of autoantibodies of type 1 diabetes and celiac disease in tuscany patients. The study aims to evaluate the concordance between the screening results obtained using two different matrix (blood drop spots on card and serum) in the search for autoantibodies for celiac disease and for type 1 diabetes. Moreover, it will be evaluated the feasibility and acceptability of the screening on a sample of the population enrolled in the territory through the participation of pediatricians.

Eligibility

Age: 2 Years – 13 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 2-13 years
* Patients with a confirmed diagnosis of type 1 diabetes or celiac disease (positive controls) and children who do not have type 1 diabetes or celiac disease or autoantibodies associated with these pathologies (controls)
* Obtained informed consent

Exclusion Criteria:

* none

Conditions4

Celiac Disease in ChildrenDiabetesDiabetes Mellitus, Type IScreening

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.